Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 08/29 10:00:08 pm
119.92 USD   +0.74%
08/26 JONSON AND JOHN : Depuy's Pinnacle Hip Replacement System
08/25 JOHNSON & JOHNS : JNJ) Janssen Biotech Inc. Files sBLA For DARZALEX
08/25 JOHNSON & JOHNS : Janssen Submits Application to the European Medici..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : FDA : J&J Unit Recalls Potentially Flammable Bone Putty

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/22/2012 | 12:13am CEST
   By Ben Fox Rubin 
 

The Food and Drug Administration said Johnson & Johnson (JNJ) unit Synthes last month initiated a recall on certain lots of bone putty, saying the medical product could catch fire during surgery.

The FDA gave the recall a Class I designation, its most serious type of recall.

The regulator said Synthes in early July issued a medical device recall letter, asking medical facilities to examine their inventories and immediately stop using specific lots of the putty. The product, called a hemostatic bone putty, is used to stop bone bleeding by creating a physical barrier along the edges of bones that have been damaged by trauma or cut during surgery.

The FDA said the putty could ignite under some conditions if contacted with certain surgical equipment.

The lots recalled were manufactured between July 6, 2011, and Dec. 14, 2011, and were distributed from Dec. 22, 2011, to June 25, 2012.

J&J in June completed its $19.7 billion purchase of medical-device maker Synthes. The health-care giant has worked to tackle a range of problem products, such as the bottles of children's Tylenol and other popular over-the-counter medicines, as well as some contact lenses and certain hip implants, that the company recalled due to manufacturing problems.

The company's shares closed Tuesday at $67.78 and were up 15 cents after hours. The stock is up 3.4% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
08/26 JONSON AND JOHNSON LAWSUIT : Depuy's Pinnacle Hip Replacement System
08/25 JOHNSON & JOHNSON : Announces Ruling Related to REMICADE® in the District of Mas..
08/25 JOHNSON & JOHNSON (NYSE : JNJ) Janssen Biotech Inc. Files sBLA For DARZALEX
08/25 JOHNSON & JOHNSON : MMIS President and CEO Michaeline Daboul to speak at CBI's 1..
08/25 JOHNSON & JOHNSON : Janssen Submits Application to the European Medicines Agency..
08/25 JOHNSON & JOHNSON : to Participate in the 2016 Wells Fargo 11th Annual Healthcar..
08/22 FOR U.S. MEDIA ONLY : Janssen Announces 25 Presentations at Upcoming ESC Congres..
08/21 JOHNSON & JOHNSON : With B.good, healthy eating comes to King of Prussia
08/21 JOHNSON & JOHNSON : Going from big pharma to farm-fresh
08/19 JOHNSON & JOHNSON : Diabetes Selfcare Demands Retail, Health Care Collaboration ..
More news
Sector news : Pharmaceuticals - NEC
10:39p Mylan to launch generic EpiPen at half the price of original
10:38p Mylan to launch generic EpiPen at half the price of original
01:56pDJMYLAN : Feeling Heat on EpiPen Price, Will Offer Cheaper Generic
11:29aDJROCHE : Receives US FDA Emergency Use Authorization for Zika Test -- Update
11:10aDJROCHE : Receives US FDA Emergency Use Authorization for Zika Test
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02:27p A MILITARY RETIREMENT PLAN : Generating Passive Income
09:45a Johnson & Johnson Vs. The S&P 500
08/27 Using My SWAN Decision Tree To Rate DGI Stocks
08/26 Is Dow Theory Telling Us The Stock Rally Is Going To Fail?
08/25 88 Stock Picks For The Next 30 Years (Or More)
Advertisement
Financials ($)
Sales 2016 72 077 M
EBIT 2016 21 808 M
Net income 2016 16 508 M
Finance 2016 13 074 M
Yield 2016 2,63%
P/E ratio 2016 20,27
P/E ratio 2017 17,86
EV / Sales 2016 4,34x
EV / Sales 2017 4,05x
Capitalization 325 679 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 127 $
Spread / Average Target 6,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.89%325 679
ROCHE HOLDING LTD.-12.84%214 671
PFIZER INC.7.87%211 206
NOVARTIS AG-10.83%210 234
ASTRAZENECA PLC7.33%173 797
MERCK & CO., INC.18.99%173 793
More Results